Pharma manufacturing is entering a stage where digitalisation is expected to improve more than documentation and reporting. Regulators and industry bodies increasingly connect advanced manufacturing with stronger process control, higher efficiency, product quality and supply reliability. The FDA describes it as new or innovatively applied medical product manufacturing technologies that can improve quality, enhance efficiency, address shortages and speed time-to-market. ISPE’s Pharma 4.0 framework also positions digitalisation as a way to create transparency, adaptability, faster decision-making and in-line control across operations, quality and compliance.
In this context, connected equipment, sensors, monitoring platforms and analytics are becoming part of production control. IoT-driven monitoring can support deviation detection, predictive alerts, environmental control and process visibility across the production floor. The value is not in collecting more data for its own sake, but in turning equipment and process signals into earlier responses.
For pharma, every operational signal can also become a quality and compliance one. When equipment behaviour, process parameters and quality data are captured with context, teams can move from reactive investigation to more proactive control. This is the shift behind smart manufacturing in pharma: from simply seeing what happens on the line to acting on it with stronger evidence.
Beyond paperless manufacturing: Why equipment and process data matter
Once connected monitoring becomes part of production control, the next question is whether the data is detailed, contextualised and reliable enough to support real operational insight. Paperless manufacturing was an important step for pharma digitalisation, but it is not the same as a fully data-driven production model. The next layer is deeper visibility into how equipment behaves, how processes perform and where early signs of deviation or instability appear.
This topic is going to be explored at AUTOMA+ 2026 in the presentation “Beyond Paperless Manufacturing: Advancing Insights into Equipment and Process Data in Bachem’s Digital Peptide Factory” by Sonja Peter, the global MES project manager at Bachem AG (AUTOMA+ 2026 Partner). The case focuses on Bachem’s new large-scale peptide manufacturing facility, where end-to-end data connectivity links production layers from ERP through MES and DCS to the historian, and back into MES. This closed loop allows process values, alarms and events to be captured, contextualised and made available for analytics.
The case also shows why scaling AIoT in pharma manufacturing depends on more than sensors or dashboards. Reliable data pipelines, OT/IT integration, contextualised alarms, interoperability between systems and validated workflows all matter. In Bachem’s example, equipment messages are classified, alarm patterns are clustered and recurring behaviours are identified to support root-cause analysis, anomaly detection and earlier troubleshooting. This is where the digital pharma factory becomes a system that can help teams understand what is happening, why it is happening and where action may be needed.
From strategy to shopfloor: Connecting performance data with operations
As equipment and process data become more available, the challenge becomes organisational as well as technical. A strategy can define goals around quality, efficiency, uptime or batch performance, but those goals only become useful when they are translated into measurable operating signals.
This executive angle is going to be addressed at AUTOMA+ 2026 by Mikko Kämäräinen, the PMO and operational excellence director at FinVector Oy through the presentation “From Strategy to Shopfloor: Digitising the Performance Cascade”. The topic focuses on how manufacturing priorities can be converted into shopfloor performance logic. In practice, this means using connected production data to link management targets with real operating conditions: where downtime occurs, how deviations affect output, whether quality signals are visible early enough and how teams can respond before performance gaps become larger operational problems.
In this sense, the performance cascade is more than a management concept – it is where AIoT, shopfloor digitalisation and pharma manufacturing KPIs meet. Connected monitoring becomes a feedback loop between strategy and daily production reality, helping teams see whether operational performance is aligned with the goals set at business level.
Digitalised production lines: Where AIoT becomes practical
At line level, connected monitoring links equipment status, sensors, process parameters, automation systems and analytics into one operating picture, so digital manufacturing can support faster troubleshooting, with less manual intervention.
The production-line perspective is going to be brought into focus at AUTOMA+ 2026 in the presentation “Innovation Solutions in Practice: Digitalised Manufacturing with the MASIRA production line” by Ernst Schranz, the CEO at GRITEC AG (AUTOMA+ 2026 Session Sponsor). MASIRA is a concrete example of digital manufacturing in practice. According to GRITEC, the platform is designed for 100% inline, non-destructive testing of medical consumables, including products such as pipettes, measuring beakers and sample containers. Its architecture includes modules for testing, stacking, line control, primary packaging, transport infrastructure and full-view checks, with line control integrating the modules and interfacing with GRITEC’s INVISTA digitalisation platform.
For pharma and medical manufacturing, the operational detail matters. MASIRA is developed for cleanroom applications, supports complete product traceability and assigns testing and measurement values to the mould cavity used for production. GRITEC also states that even with 64 cavities and a 20% scrap rate, MASIRA maintains a 5.5-second cycle time. This kind of digitalised production line use case shows why AIoT is becoming relevant beyond pilot projects: it connects automation, monitoring, quality control and traceability in a real manufacturing environment.
Why these questions matter for AUTOMA+ 2026
The next stage of pharma digitalisation will not be defined by one tool or one platform. It will depend on how well companies can connect production data, operational targets and real manufacturing constraints into systems that support better decisions.
For pharma teams working across manufacturing, automation, digitalisation, quality, engineering and IT, AUTOMA+ 2026 brings these questions into one setting. The Congress gives space to implementation experience, practical case studies and the operational realities behind AIoT adoption, making the discussion relevant not only to digital strategy, but to how modern pharma production is measured, controlled and improved.
Join AUTOMA+ 2026 to explore how pharma companies are applying AIoT, IoT-driven monitoring and digital manufacturing technologies in real production settings.
